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Abstract. The amyloid plaques and neurofibrillary tangles found in the Alzheimer’s disease (AD) brain arise as a result of self-
assembly into fibrillar material of amyloid- protein (A) and hyperphosphorylated tau, respectively, through a pathological
process starting with the appearance of aggregation nuclei and neurotoxic oligomers. Accordingly, the search of inhibitors of
oligomer nucleation and growth is considered a promising target to prevent amyloid toxicity. In recent years, a number of dietary
factors including antioxidants, vitamins, and polyphenols have been characterized for their ability to protect cells stressed
by several factors including the presence of amyloid deposits as well as to inhibit amyloid self-assembly and cytotoxicity
and some of them are currently in clinical trial. The present review summarizes the findings on the beneficial effects against
neurodegeneration and other peripheral inflammatory and degenerative diseases of oleuropein aglycone (OLE), a natural phenol
abundant in the extra virgin olive oil. The data presently available suggest that OLE could provide a protective and therapeutic
effect against a number of pathologies, including AD as well as obesity, type 2 diabetes, non-alcoholic hepatitis, and other natural
or experimentally-induced pathological conditions. Such a protection could result, at least in part, in a remarkable improvement
of the pathological signs arising from stress conditions including oxidative stress, an excessive inflammatory response, and
the presence of cytotoxic aggregated material. In particular, the recent data on the cellular and molecular correlates of OLE
neuroprotection suggest it could also play a therapeutic role against AD.
Keywords: Alzheimer’s disease, amyloid- deposits, autophagy, epigenetics, polyphenols, TgCRND8 mice
∗Correspondence to: Fiorella Casamenti, Department of Neuro-
science, Psychology, Drug Research and Child Health, Division
of Pharmacology and Toxicology, University of Florence, 50139
Florence, Italy. Tel.: +39 055 4271242; Fax: +39 055 4271280;
E-mail: fiorella.casamenti@unifi.it.
INTRODUCTION
Focusing dietary regimens associated with a reduced
risk of degenerative diseases in the aged population
can be useful to find molecules exploitable for their
prevention and therapy. Mounting evidence supports
the beneficial effects of the Mediterranean and Asian
diets in delaying aging and in preventing age-related
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dysfunctions, cancer, diabetes, and neurodegener-
ative diseases [1–5]. In particular, Mediterranean
diet appears effective against AD-like pathology and
cognitive deterioration, attenuating mild cognitive
impairment and its conversion to AD. The benefi-
cial effects of the Mediterranean and Asian diets in
reducing age-related dysfunctions could be the conse-
quence of the presence, in specific foods characterizing
those alimentary regimens, of substantial amounts
of specific polyphenols whose beneficial properties
include the ability to interfere with amyloid aggre-
gation [7–10]. Oleuropein and its aglycone (OLE)
are the major polyphenols in the leaves and drupes
of Oleaceae, particularly Olea Europaea, yet with
different abundancies in the various cultivars, and
in the extra virgin olive oil (EVOO) thereof [11].
Studies in rodents suggest that diet supplementation
with phenol-rich components of the Mediterranean
diet such as red wine and EVOO improves several
pathological conditions, with particular emphasis on
aging- and disease-associated cognitive and behavioral
deficits [12]. Similar data have been reported for other
polyphenols, such as curcumin and epigallocatechin-
3-gallate found in turmeric and green tea, respectively,
abundantly consumed in the Asian diet [13, 14].
It was previously found that OLE interferes with
amylin [15], tau [16], and A peptide aggregation and
toxicity both in vitro [7] and in an A expressing
C. elegans transgenic strain [17]. Subsequently, the
implementation of that research carried out with the
TgCRND8 mouse model of A deposition showed that
OLE administration results in a significant reduction of
soluble and aggregated A in AD-relevant brain areas
with a significant attenuation of A-mediated cogni-
tive deterioration [5, 18]. This mini-review summarizes
the main results that have led to suggest the useful-
ness of OLE to combat, among other, age-associated
neurodegeneration and dementia.
OLE COUNTERACTS THE SIGNS OF A
NUMBER OF DEGENERATIVE
CONDITIONS RESULTING FROM
OXIDATIVE STRESS AND
INFLAMMATION
Previous studies carried out in vivo such as those per-
formed with mice models of spinal cord injury [19],
carrageenan-induced pleurisy [20], collagen-induced
arthritis [21], and intestinal ischemia-reperfusion
injury [22] have shown that OLE possesses remarkable
anti-inflammatory activity [23]. Other studies have
indicated that OLE possesses other biochemical and
pharmacological activities, including cardioprotective,
antioxidant, antiatherogenic, anticancer, antimicro-
bial, and antiviral effects (reviewed in [24]). Finally,
it has been reported that OLE and other polyphenols
found in olive oil are able to prevent low density
lipoprotein oxidation and platelet aggregation and to
inhibit lipoxygenase and eicosanoid production [25].
For all these reasons in recent years OLE has become
an important subject of study. In particular, the effects
of OLE and other natural polyphenols on living sys-
tems recall those produced by a healthy level of caloric
restriction, which is recommended to improve aging
reducing the risk of age-associated diseases, including
dementia. These similarities have led to propose that
the beneficial effects of the Mediterranean/Asian diets
result from their rich content of polyphenols [26].
OLE PROTECTS AGAINST TYPE 2
DIABETES AND OTHER CONDITIONS
THAT CHARACTERIZE THE METABOLIC
SYNDROME
Besides the protective effects against a number of
pathologies with uncontrolled oxidative stress and
inflammatory reaction outlined above, recent research
has shown the effectiveness of OLE against obesity
[27], type 2 diabetes [28] and the hepatic steato-
sis induced by a high-fat diet in mice [29]. Taken
together, these data support a beneficial action of
OLE against some of the signs of the metabolic syn-
drome, a complex pathological condition affecting an
increasing number of people in advanced countries.
In particular, OLE supplementation to high-fat diet
mice reversed the increase of liver weight together with
that of hepatic and plasma lipid levels; this occurred
possibly through downregulation of the expression
of Wnt10b-inhibitor genes and the Toll-like receptor-
mediated signaling molecules (TLR2, TLR4) and
pro-inflammatory cytokines. The expression of several
transcription factors and their target genes involved
in adipogenesis, was also downregulated, whereas the
expression of -catenin was upregulated [29]. These
results have led these authors to suggest that OLE
protects against high fat-induced hepatic steatosis in
mice through Wnt10b- and fibroblast growth factor
receptor-1 (FGFr1)-mediated signaling involved in
liver lipogenesis together with TLR2 and TLR4 sig-
naling involved in hepatic steatosis.
A recent randomized, double-blind, placebo-
controlled crossover trial was carried out in New
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Zealand with 46 middle-aged participants, with
medium-high body-mass index and at risk of devel-
oping the metabolic syndrome, receiving an oral dose
of OLE (50 mg+10 mg hydroxythyrosol) or of placebo
for 12 weeks. At the end of the treatment, the results
showed that, as compared to placebo, people fed with
OLE displayed a 15% improvement in insulin sen-
sitivity and a 28% improvement of pancreatic -cell
responsiveness and secretory capacity, with increased
concentrations of interleukin 6 (IL-6) and insulin-like
growth factor-binding protein 1/2 (IGFBP-1/2), with-
out any evident negative effect on hepatic and other
physiological parameters [28]. Taken together, these
data agree with those previously reported on OLE inter-
ference with the normal path of amylin aggregation in
vitro with lack of appearance of cytotoxic oligomers
[15].
PLANT POLYPHENOLS ARE EFFECTIVE
AGAINST ALZHEIMER’S DISEASE
AD is the most common form of dementia presently
affecting, in developed countries, approximately 30
million aged people, and those numbers are expected
to triple by 2050. The key histopathological sign of
AD is the presence, in several brain areas, of hyper-
phosphorylated tau aggregates and tangles, of minute
extracellular amyloid (A) deposits found in diffuse
and senile plaques and around cerebral vessels and dys-
trophic/degenerating neurites. Plaque deposits, mainly
composed of polymeric fibrils of the 42 amino acid
peptide (A42) generated by membrane amyloid-
protein precursor proteolysis [30, 31], are thought to
be responsible for the functional alterations and behav-
ioral deficits that characterize AD [30]. Recently, the
interest in deciphering the relationship between plaque
burden and neuronal death has focused on the impor-
tance, as the main neurotoxic species, of the oligomeric
pre-fibrillar assemblies originating at the onset of fibril
growth [32]. The latter evidence contributed to explain
the lack of relation between plaque load and AD sever-
ity [33]; it also shifted the search of treatments able
to delay AD occurrence and to relieve its symptoms
from the development of molecules able to hinder fibril
growth to that of molecules effective in counteract-
ing the appearance of toxic oligomeric intermediates
[34]. Several therapeutic approaches inhibiting amy-
loidogenic protein self-assembly into oligomers and
fibrils are under development; in particular, increasing
interest is devoted to the anti-amyloidogenic activity
of plant polyphenols present in several foods such as
resveratrol, OLE, curcumin, and epigallocatechin-3-
gallate [8]. In particular, recent work has provided
the most complete set of data concerning the ben-
eficial effects of OLE [5, 7, 17, 18]. These include
the behavioral, biological, biophysical, biochemical,
and electrophysiological correlates of OLE protection
against neurodegeneration which characterizes AD.
OLE REDUCES COGNITIVE IMPAIRMENT
AND IMPROVES SYNAPTIC FUNCTION IN
TgCRND8 MICE
The beneficial effects of dietary supplementation of
OLE were investigated in the TgCRND8 (Tg) mice, a
widely used model of A deposition [5, 18]. These Tg
mice are cognitively impaired by the age of 3 months
[35] and develop a pattern of A deposition recalling
several aspects of human AD [36, 37]. By the same
age, mice display small sized A42-immunopositive
plaques in various brain areas, including the cortex
and the hippocampus. Upon aging, plaque number
increases, reaching the maximum roughly by 7–9
months of age; moreover, the plaques become larger,
from small-medium to big in size and radiating in
shape and acquire a compact core [36]. In addition,
in later life stages, from 6 to 12 months of age,
this Tg strain exhibits, throughout the cortical and
hippocampal areas, plaques with a huge amount of
pyroglutamylated 3-42A (pE3-A) largely exceed-
ing that of A42 [18]. This A42 derivative is produced
by the activity of glutaminyl cyclase (QC) and is
increasingly considered a key player in A aggregation
and plaque growth [38]. Two types of pE-A plaques
are found in the human hippocampus, focal and diffuse,
the former associated with QC-expressing interneu-
rons [39] thus supporting the close pE-A/QC relation
and its association with cognitive decline in AD [40].
Moreover, the finding that QC expression and pE-A
burden increase with Braak stages [41] further stresses
the importance of these factors in AD pathogenesis.
Wild type (wt) and Tg mice of three age groups
(1.5, 4.0 and 10.0 months) were treated for 8 weeks
with a modified low-fat (5.0%) AIN-76A diet either
as such (untreated mice) or supplemented with 50 mg
OLE/kg of diet (OLE-fed mice) [5], following DL
116/92, Directive 86/609/EEC and National guide-
lines for animal care (P.N. 283/2012-B). At the end
of treatment, the wt and Tg mice were checked for
cognitive performance. Untreated 3–6-month old Tg
mice were unable to memorize the punishment and
to perform the inhibitory avoidance in the step-down
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passive avoidance test; they were also unable to dis-
criminate between the familiar and the novel object
in the object recognition test [5]. However, OLE-fed
mice displayed a remarkable improvement in both
behavioral tests, with scores reaching those displayed
by age-matched wt controls. The improved results in
cognitive tests were associated with a significant ame-
lioration of synaptic function, as assessed by long-term
potentiation experiments in CA1 hippocampal slices
of aged Tg mice incubated with OLE or with vehicle
1.0 h before and during all electrophysiological record-
ings [18]. Interestingly, similar results were obtained
with slices exposed to suberoylanilide hydroxamic acid
(SAHA), an histone deacetylase-2 inhibitor, suggest-
ing some epigenetic involvement (see below).
OLE REDUCES SOLUBLE A, PLAQUE
LOAD/DENSITY, AND GLIA REACTION IN
TgCRND8 MICE
The improvement of OLE-fed Tg mice in cognitive
tests was accompanied by a significant reduction of
A40/A42 and pE3-A levels and A plaque size and
compactness in the brain tissue, in agreement with the
in vitro anti-aggregation effect of OLE [7, 18]. In the
older Tg mice, OLE administration not only prevented
amyloid deposition but also favored disaggregation of
preformed plaques [5], that appeared “fluffy” and less
cored in the neuron surroundings (Fig. 1). In the hip-
pocampus and cortices of 12-month-old OLE-fed Tg
mice, Thioflavin S staining, which marks A fibrils,
revealed a significant reduction in the number and total
A plaque area (Fig. 2A, B); moreover, most plaques
displayed reduced size and a ribbon-like/diffuse core,
as compared to those imaged in untreated Tg mice.
As we already reported employing OC and pE3-A
antibodies [18], in both OLE-fed and untreated 12-
month-old Tg mice an overlap of the staining of the
pE3-A (blue) and Thioflavin S (green) was detected
in the entire plaque where pE3-A blue staining was
particularly intense in the plaque core (Fig. 2A). This
effect was also the consequence of a significant reduc-
tion of QC expression in the brain of OLE-fed mice,
whereas the polyphenol had no effect on QC activity
in vitro [18]. The molecular mechanism of this find-
ing has not been determined; however, it appears to be
of critical importance to drive the beneficial effects of
OLE associated with plaque load reduction.
As already reported for young/middle-aged Tg mice
[5], A40 and A42 sodium dodecyl sulphate and
formic acid soluble fractions measured in the cortex
of 12-month-old OLE-fed Tg mice were significantly
reduced as compared to untreated Tg mice (Fig. 2C).
Furthermore, in the aged OLE-fed Tg mice, the
decreased A load was paralleled by a less intense A-
associated glia reaction, in terms of reduced astrocyte
activation, as shown by the presence of fewer and less
reactive astrocytes throughout the brain and reduced
glial fibrillary acidic protein levels (Fig. 3).
OLE TRIGGERS AUTOPHAGY
In AD, plaque load results from complex equi-
libria between A deposition and clearance, where
Fig. 1. Representative photomicrographs showing neurons (green) within compact and fluffy amyloid plaques, stained by OC antibody (red),
in untreated and OLE administered TgCRND8 mice.
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Fig. 2. Thioflavin S staining in untreated and OLE-fed TgCRND8 mice. A) OLE administration reduces Thioflavin S positive plaque burden
(green) in the hemibrain of 12-month-old TgCRND8 mice; pE3-A (blue) and Thioflavin S (green) staining co-localizes in cored A deposits
of both Tg groups. B) Quantitative analysis of Thioflavin S stained plaque area and plaque number in 12-month-old untreated and OLE-fed Tg
mice (n = 5/group, six sections/mouse) in the parietal and piriform cortices and in the hippocampus (squared areas indicate in the left hemibrain
image). C) ELISA: cortical levels of sodium dodecyl sulphate- and formic acid-soluble A40 and A42 peptides. Both A40 and A42 levels
were significantly decreased in OLE-fed Tg versus age-matched untreated Tg mice (n = 5/group). Data are reported as mean values ± S.E.M.
Statistical analysis: two-tailed unpaired Student’s t-test.
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Fig. 3. Glial fibrillary acidic protein (GFAP) immunoreactivity and levels in untreated and OLE-fed TgCRND8 mice. A) Left panels, reconstruc-
tion of representative photomicrographs of GFAP immunoreactivity in the cortex and hippocampus of 12-month-old untreated and OLE-treated
Tg mice; Right panels: hypertrophic astrocytes (green) with long and thick branches were detected in the brain of untreated Tg mice in the plaque
(red, OC antibody) surroundings. In OLE-fed animals astrocyte (green) activation in the fluffy plaque (red, OC antibody) surroundings was
considerably milder. B) Western blotting quantitative analysis of GFAP levels in the hippocampus of 12-month-old OLE-fed Tg and untreated
wt and Tg mice, n = 5-6 mice/group (∗p < 0.05, wt versus Tg OLE; ∗∗p < 0.01wt versus Tg; One Way ANOVA plus Newman-Keuls Multiple
Comparison Test).
autophagy (namely macroautophagy), a mammalian
target of rapamycin (mTOR)-dependent lysosome-
mediated catabolic pathway responsible for turnover
of long-lived proteins and organelles, appears to play
a key role. Autophagy protects neurons against envi-
ronmental stresses such as starvation and A-induced
cytotoxicity, suggesting its possible role in A clear-
ance. The picture is made even more complex by
the data showing that increased mTOR signaling, and
hence depressed autophagy, seems to be induced by
A peptides; accordingly, it has been suggested that
A-mediated mTOR activation could contribute to
early cognitive deficits in AD. These and other data
support the notion that autophagic dysfunction may
represent a key molecular link between brain aging,
A accumulation in the brain parenchyma, and cog-
nitive impairment. By contrast, autophagy stimulation
[43] or reversal of autophagy dysfunction by differ-
ent treatments has been shown to ameliorate amyloid
pathologies [42] such that it is increasingly recognized
that induction of autophagy might be useful to pro-
tect against neurodegeneration and A peptide toxicity
[44, 45].
We have recently found a remarkable induction
of the autophagic pathway in the cortex of OLE-
fed young and old Tg mice. In these animals, OLE
administration triggers the autophagic machinery and
favors autophagosome substrate delivery to lyso-
somes for cargo degradation [18]. Specifically, a
strong punctuate immunoreactivity and higher levels of
autophagosome-lysosome markers such as Beclin-1,
the lipidated derivative of LC3 and cathepsin B, were
detected in the cortex and, to a lesser extent, in hip-
pocampal areas of OLE-fed Tg mice at all stages of
the pathology, as compared to untreated age-matched
controls [5, 18]. Although to a lesser extent than in
OLE-fed Tg mice, Beclin-1 and LC3 immunoreactivi-
ties were also more intense in OLE-fed wt mice than in
untreated animals, supporting a general effect of OLE
as an autophagy inducer.
Various signaling pathways are involved in
macroautophagy stimulation. As pointed out above,
the canonical pathway involves mTOR Complex 1
(mTORC1), a cytosolic complex of five proteins
including mTOR, a primordial negative regulator of
autophagy. mTOR is inhibited by stress conditions
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Fig. 4. Schematic representation of effects and cellular targets of OLE in TgCRND8 mice.
such as starvation that result in activation of mTOR
targets. mTOR inhibitors such as rapamycin display
similar effects, leading to propose it as a new tool
to fight neurodegeneration [43]. Autophagy can be
triggered also by mTOR inhibition through phospho-
rylation by AMP-activated protein kinase (AMPK),
a stress-induced kinase activated by phosphoryla-
tion triggered with a number of signals associated
with cellular energy homeostasis such as an increase
of the AMP/ATP ratio and the serine/threonine
kinase liver kinase B1 (LKB1) [47]. AMPK can
also be activated by a rise of the cytosolic Ca2+.
The resulting Ca2+/calmodulin complex activates the
calcium/calmodulin-dependent protein kinase kinase 2
(CAMKK2), a kinase expressed in the CNS where it
plays key roles in axon and synaptic plasticity; in turn,
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the activated CAMKK activates AMPK by phosphory-
lation [48]. In our mouse model, autophagy activation
by OLE could not directly involve mTOR; in fact, our
unpublished data with OLE-exposed cultured SHSY-
5Y cells suggest that in these cells of neuronal type
autophagy is triggered following AMPK activation.
OLE MODULATES EPIGENETICS IN Tg
MICE
Accumulating evidence indicates epigenetic dereg-
ulation (DNA methylation, histone methylation,
acetylation, and phosphorylation) of gene expression
in many pathological states, from cancer to cardiovas-
cular diseases and metabolic disorders; in particular,
epigenetics appear to play an important role in age-
related memory impairment and in the pathogenesis
of neurodegenerative diseases. In particular, proper
levels of histone acetylation appear of the outmost
importance to delay aging and to hinder neurodegen-
eration. Histone acetylation is thought to be associated
with an “open” chromatin conformation and tran-
scriptional activation, while histone deacetylation is
considered to be involved in transcriptional repression
resulting from a “closed” chromatin structure [49].
Histone acetylation levels are the result of a balance
between the activities of histone acetyltransferases and
histone deacetylases (HDACs). Abnormal acetylation
of histones is involved in learning and memory and
might be causally associated to AD pathogenesis [50];
moreover, histone acetylation seems to ameliorate cog-
nitive deficits in AD animal models [51]. In particular,
HDACs, isoform 2, appear to be upregulated in the
AD brain, thus reducing the level of histone acetyla-
tion and blocking DNA transcription at specific loci.
In AD brains, the HDAC2 levels are increased [50]
and the balance of histone 3 acetylation is disrupted by
soluble A [52].
The above reported results concerning remarkable
modifications of the expression of QC and autophagy
markers in our OLE-fed Tg mice, together with the
effect of SAHA in restoring long-term potentiation
in hippocampal slices mimicking that resulting from
OLE exposure, supported some involvement of epi-
genetic modulations by OLE [18]. Our initial study
on the OLE-epigenetics relationship has shown that in
our TgCRND8 mice HDAC2 expression is increased
concomitantly with the reduction of histone 3 and 4
acetylation throughout the cortex and the hippocam-
pus, both contributing to their cognitive impairments
and synaptic dysfunctions. Those modifications were
fully reverted by OLE treatment [18], even though the
mechanistic basis of this effect has not been elucidated
yet. Our data support the idea that epigenetic mech-
anisms, particularly some modification of the histone
acetylation level, underlie the neuroprotective effects
of OLE and, therefore, can be considered as a new
approach to prevent and, possibly, to treat AD patients.
On the other hand, presently AD treatments are lim-
ited to symptomatic relief, whereas effective therapy is
not available yet. Our findings agree with recent data
suggesting that the development of effective HDAC
inhibitors could be a new promising therapeutic strat-
egy to fight AD [51].
CONCLUSIONS
The beneficial effects of the Mediterranean and
Asian diets stem from many factors. An important role
is increasingly attributed to the content of polyphe-
nols of several foods, including olive oil, red wine,
green tea, and spices. Differently from resveratrol,
curcumin, and epigallocatechin-3-gallate, extensively
studied for their healthy properties, much less knowl-
edge is available on olive oil polyphenols, including
OLE. However, recent finding from our and other
groups have addressed this theme providing valuable
data on the molecular and cellular basis of the ben-
eficial effects of these polyphenols against type 2
diabetes [53], liver steatosis [29], obesity [27], and
age-associated neurodegeneration [9].
For what A-induced neurodegeneration is con-
cerned, recently reported findings indicate that OLE
administration to Tg mice improves memory and
behavioral performance by interfering with A aggre-
gation and restoring the transgene-associated different
dysfunctional aspects in the brain of our mouse model
of AD. The identified cellular targets include plaque
deposition, size, and compactness, the pE3-A/A42
ratio, the inflammatory and the autophagic/lysosomal
responses, epigenetics, and the synaptic function
(Fig. 4). In conclusion, our results suggest that
OLE supplementation could be considered as a new
approach to prevent, to delay, and, possibly, to treat
AD.
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